Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 edition)
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are firstly diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the syst...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2022-07-01
|
Series: | Liver Cancer |
Online Access: | https://beta.karger.com/Article/FullText/526038 |